OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
J Venom Res
Open-access
Aptamers
Open-access
Aptamers 2019
03-04 April 2019, Oxford
Submit a manuscript

RNAi2010

RNAi2010-banner1

 

RNAi2010-Sponsors

 

Dr Erik Miska, University of Cambridge, UK
The complex life of small RNAs

Professor Dr Georg Sczakiel, University of Lübeck, Germany
Cell stress-induced translocation of human Argonaute 2 protein is related to decreased RNA interference

Dr Stephanie Urschel, Thermo Scientific Genomics
A workflow for studying miRNA expression and identifying miRNA targets

Dr Charles Lawrie, University of Oxford, UK
MicroRNA expression in lymphoma

Dr Brian Schyth, Technical University of Denmark, Denmark
In vivo screening of backbone-modified siRNAs for their ability to induce interferone-based off-target effects

Dr Jörg Vollmer, Pfizer-Coley, Germany
Novel ways to modify immune modulation by DNA and RNA therapeutics

Dr Cecilia Lundin (Sponsored by PerkinElmer), University of Oxford, UK
RNAi screens to determine homologous recombination networks

Dr Dmitry Samarsky, RXi Pharmaceuticals, USA
Combination of oligo configuration and chemical modification provides drug-like properties to RNAi molecules

Dr Attila Seyhan, Pfizer-Wyeth, USA
Whole-genome RNAi screens to identify novel modulators of breast cancer genes

Dr William Arthur, Merck & Co, Inc, USA
Identification of new regulators of the Wnt-ß-catenin pathway via RNAi screening

Dr Tobias Poehlmann, Friedrich-Schiller-Universität Jena, Germany
Development of small interfering RNA, selectively activated in target cells

Dr Glen Reid, University of Sydney, Australia
A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5′ RACE and a molecular beacon probe

Dr Luc JW van der Laan, Erasmus MC-University Medical Center, The Netherlands
Cell-to-cell transmission of small RNAs extends the therapeutic reach of RNAi

Ms Mariam Sharaf, Duke University, USA
Boranophosphate-modified RNA as potential anti-cancer therapeutic: Aptamers and RNA interference

Ms Dana Danielson, Steacie Institute of Molecular Sciences, Canada
Modifying p19 viral suppressors of RNA Silencing: Developing FRET-based probes for detecting and quantifying protein-small RNA interactions

Dr Sandra Laufer, University of Lübeck, Germany
Mechanistic studies of siRNA-mediated RNA interference in HeLa cell extract

18 March

 

Dr Petr Svoboda, Institute of Molecular Genetics, Czech Republic
Useless microRNAs in mammalian oocytes

Dr Martin Fabani, University of Cambridge, UK
Evaluation of peptide nucleic acids for in vivo inhibition of microRNA-155

Dr Jens Kurreck, University of Stüttgart, Germany
RNA interference approaches to inhibit cardiotropic viruses

Dr Graeme Doran, Massachusetts Institute of Technology, USA
Modular elements modulating RNA stability

Dr Zdravka Medarova, Massachussetts General Hospital, USA
Image-guided siRNA delivery

Dr Patrick Lu, Sirnaomics, Inc, USA
Multi-targeted siRNA therapeutics with three generations of nanoparticle delivery

Dr Roger Adami, MDRNA, Inc, USA
A novel amino acid based delivery platform for therapeutic applications in bladder cancer and hepatocellular carcinoma

Professor Andy Miller, Imperial College London, UK
Designing safe, self-assembly nanoparticles that enable nucleic acid therapeutics, molecular imaging and theranostics

Dr Seyed Javad Mowla, Tarbiat Modares University, Iran
Induction of apoptosis in tumour cell lines by suppressing the expression of OCT4B1 – a novel spliced variant of OCT4

Leave a Reply